Regeneron Pharmaceuticals
REGN
512 hedge funds and large institutions have $29.6B invested in Regeneron Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 87 funds opening new positions, 174 increasing their positions, 189 reducing their positions, and 43 closing their positions.
102% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 43
46% more funds holding in top 10
Funds holding in top 10: 13 → 19 (+6)
14% more capital invested
Capital invested by funds: $25.9B → $29.6B (+$3.71B)
8% more funds holding
Funds holding: 474 → 512 (+38)
8% less repeat investments, than reductions
Existing positions increased: 174 | Existing positions reduced: 189
25% less call options, than puts
Call options by funds: $590M | Put options by funds: $790M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$283M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$267M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$193M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$106M |
| 5 |
JP Morgan Chase
New York
|
+$85.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$390M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$218M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$80.8M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$78.7M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$64.3M |
REGN Hedge Fund Activity: Q4 2014 in Review
512 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2014, worth a combined $29.6B — up 14% from $25.9B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new REGN positions and 43 closed out — a net gain of 44 holders — while 174 added to existing stakes and 189 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $283M. The largest seller was Viking Global Investors, exiting entirely with an estimated $390M sold.
- 512 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2014, up from 474 in Q3 2014.
- Funds reported $29.6B of Regeneron Pharmaceuticals stock for Q4 2014, up 14% quarter-over-quarter.
- 87 funds opened new Regeneron Pharmaceuticals positions in Q4 2014 and 43 closed out, a net change of +44 holders.
- The largest Regeneron Pharmaceuticals buyer in Q4 2014 was Fidelity Investments, an estimated $283M added.
- The largest Regeneron Pharmaceuticals seller in Q4 2014 was Viking Global Investors, an estimated $390M sold.
Based on aggregated 13F filings for Q4 2014.